Interobserver and Intraobserver Variability of Standardized Uptake Value Measurements in Non–small-cell Lung Cancer
暂无分享,去创建一个
L. Broemeling | G. Gladish | R. Munden | O. Mawlawi | D. Podoloff | J. Bruzzi | M. Truong | H. Macapinlac | E. Marom
[1] H. Schäfers,et al. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. , 2004, The Journal of thoracic and cardiovascular surgery.
[2] S. Larson,et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Pevsner,et al. The CT motion quantitation of lung lesions and its impact on PET-measured SUVs. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] Mithat Gonen,et al. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] Kenneth E Rosenzweig,et al. Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: methodology and comparison with respiratory gated PET. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[6] J Nuyts,et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). , 2003, European journal of cancer.
[7] M. Schwaiger,et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] S. Larson,et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Keigo Endo,et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. , 2002, American journal of surgery.
[10] D. Mankoff,et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. , 2002, Academic radiology.
[11] J. Wildberger,et al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma , 2002, Bone Marrow Transplantation.
[12] Mohamed Allaoua,et al. Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Fischman,et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. , 2002, Lung cancer.
[14] J. Vansteenkiste. Imaging in lung cancer: positron emission tomography scan , 2002, European Respiratory Journal.
[15] Elisabeth Kjellén,et al. FDG PET studies during treatment: Prediction of therapy outcome in head and neck squamous cell carcinoma , 2002, Head & neck.
[16] D. Visvikis,et al. Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET , 2001, European Journal of Nuclear Medicine.
[17] Sung-Cheng Huang,et al. Anatomy of SUV , 2000 .
[18] M. O'Doherty,et al. [(18)F]Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. , 2000, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[19] A. Gregor,et al. Randomized trial of surgery versus radiotherapy in patients with stage IIIA (N2) non small-cell lung cancer after a response to induction chemotherapy. EORTC 08941. , 2000, Clinical lung cancer.
[20] John L. Humm,et al. Use of PET to monitor the response of lung cancer to radiation treatment , 2000, European Journal of Nuclear Medicine.
[21] P A Salvadori,et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. , 2000, Clinical breast cancer.
[22] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[23] John L. Humm,et al. Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[24] D. Altman,et al. Measuring agreement in method comparison studies , 1999, Statistical methods in medical research.
[25] P. Dupont,et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIa-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] R. Coleman,et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma , 1998, Cancer.
[27] N. Choi,et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M Schwaiger,et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. , 1996, Journal of the National Cancer Institute.
[29] M Schwaiger,et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] J. Keyes. SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[31] T. Olencki,et al. Accelerated induction therapy and resection for poor prognosis stage III non-small cell lung cancer. , 1995, The Annals of thoracic surgery.
[32] J. Crowley,et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] R L Wahl,et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. , 1995, Radiology.
[34] J. Bergh,et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J M Hoffman,et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] J. Roth,et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. , 1994, Journal of the National Cancer Institute.
[37] J. Mate,et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.
[38] O. Hoekstra,et al. Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography , 1993, European Journal of Nuclear Medicine.
[39] M. Kris,et al. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] M. Kris,et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. , 1993, The Annals of thoracic surgery.
[41] N. Choi,et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] S. Steinberg,et al. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. , 1992, The Annals of thoracic surgery.
[43] P. Valk,et al. Assessment of Treatment Response by FDG-PET , 2006 .
[44] D. Podoloff,et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] Frank Griesinger,et al. Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. , 2003, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[46] N. Sadato,et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[47] C. E. al. Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma , 2002, Bone Marrow Transplantation.
[48] Yukiko Arisaka,et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[49] S. Larson,et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. , 2002, The Annals of thoracic surgery.
[50] S C Huang,et al. Anatomy of SUV. Standardized uptake value. , 2000, Nuclear medicine and biology.
[51] J. Menten,et al. Present status of induction treatment in stage IIIA-N2 non-small cell lung cancer: a review. The Leuven Lung Cancer Group. , 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[52] J. Clark,et al. Combined modality therapy for stage IIIA non-small cell carcinoma of the lung. , 1993, European journal of cancer.